Patent 7244609 was granted and assigned to Cayla on July, 2007 by the United States Patent and Trademark Office.
The invention relates to a new series of bacterial plasmid vectors which are fully devoid of CpG and which can express synthetic genes which do not contain CpG in the bacteria Escherichia coli.